Document series
Trial abstracts — page 6
700 structured trial abstracts. Each is one document in five parts: abstract, design and population, results, certainty assessment and citing documents.
Showing 0 records on this page
Trial records
700 documents · page 6 of 30
Table 1. Trial records on this page. The table sorts on any column and filters on the controls above; both operate on the records shown on this page only.
| Record | Compound | Phase | Status | Design | Randomised | Year | Certainty |
|---|---|---|---|---|---|---|---|
| GHKCU-TOPICAL-1 | GHK-Cu | Phase 2 | Reported | Randomised, double-blind, placebo-controlled | — | 2005 | Low |
| TA1-HCV-1 | Thymosin alpha-1 | Phase 3 | Reported | Randomised, double-blind, active-controlled | — | 2004 | Moderate |
| PRAM-T2D-1YR | Pramlintide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | 656 | 2003 | Moderate |
| PRAM-T1D-PIVOTAL | Pramlintide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | 480 | 2002 | Moderate |
| TA1-HBV-1 | Thymosin alpha-1 | Phase 3 | Reported | Randomised, double-blind, active-controlled | — | 2001 | Moderate |
| IPA-PH1-GH | Ipamorelin | Phase 1 | Reported | Phase 1 ascending dose | — | 1998 | Low |
| TA1-VACCINE-ELDERLY | Thymosin alpha-1 | Phase 2 | Reported | Randomised, double-blind, placebo-controlled | — | 1998 | Moderate |
| HEX-PH2-ELDERLY | Hexarelin | Phase 2 | Reported | Randomised, double-blind, placebo-controlled | — | 1997 | Low |
| GHRP6-PH1-GH | GHRP-6 | Phase 1 | Reported | Phase 1 ascending dose | — | 1995 | Low |
| HEX-PH1-GH | Hexarelin | Phase 1 | Reported | Phase 1 ascending dose | — | 1995 | Low |
| BPC-PH2-UC | BPC-157 | Phase 2 | No retrievable report | Randomised, double-blind, placebo-controlled | — | — | Not rated |
| DREAMS-3 | Mazdutide | Phase 3 | Ongoing | Randomised, double-blind, active-controlled | — | — | Not rated |
| DSIP-HIST-SLEEP | DSIP | — | No retrievable report | Randomised crossover | — | — | Not rated |
| EPI-RU-ELDERLY | Epithalon | — | No retrievable report | Observational | — | — | Not rated |
| GNRH-DIAGNOSTIC | Gonadorelin | — | Reported | Diagnostic accuracy | — | — | Moderate |
| GNRH-PULSATILE-HH | Gonadorelin | — | Reported | Single-arm open-label | — | — | Moderate |
| MARITIDE-PH3 | Maridebart cafraglutide | Phase 3 | Ongoing | Randomised, double-blind, placebo-controlled | — | — | Not rated |
| PETRE-PH2-OBESITY | Petrelintide | Phase 2 | Ongoing | Randomised, double-blind, placebo-controlled | — | — | Not rated |
| REDEFINE-4 | CagriSema (cagrilintide with semaglutide) | Phase 3 | Ongoing | Randomised, double-blind, active-controlled | — | — | Not rated |
| SELANK-RU-ANXIETY | Selank | — | No retrievable report | Observational | — | — | Not rated |
| SEMAX-RU-COGNITIVE | Semax | — | No retrievable report | Observational | — | — | Not rated |
| SEMAX-RU-STROKE | Semax | — | No retrievable report | Observational | — | — | Not rated |
| SERM-DIAGNOSTIC | Sermorelin | — | Reported | Diagnostic accuracy | — | — | Moderate |
| SYNCHRONIZE-1 | Survodutide | Phase 3 | Ongoing | Randomised, double-blind, placebo-controlled | — | — | Not rated |
page 6 of 30